| CPC G01N 33/505 (2013.01) [G01N 33/6893 (2013.01); G01N 2333/5409 (2013.01); G01N 2333/5437 (2013.01); G01N 2800/06 (2013.01)] | 18 Claims |
|
1. A method for treating eosinophilic gastrointestinal disorder (EGID) in a human subject in need thereof, the method comprising
detecting thymic stromal lymphopoietin (TSLP) responsive cells in a sample of whole blood obtained from the subject by
contacting cells in vitro with TSLP without stimulation of the cells with anti-CD3 or anti-CD28 antibodies, wherein the cells are selected from PBMC, CD4+ T cells, or memory CD4+ T cells, and
detecting one or more analytes in the cells or secreted by the cells, the one or more analytes selected from phosphorylated signal transducer and activator of transcription 5 (pSTAT5), interleukin-5 (IL-5), and interleukin-13 (IL-13),
wherein the detection of the one or more of the analytes indicates TSLP responsive cells in the blood of the human subject,
determining whether an amount of the one or more analytes is above or below a predetermined diagnostic threshold, wherein an amount above the threshold indicates an EGID status of active disease for the subject and an amount below the threshold indicates that an EGID status of managed, and
administering an EGID therapy to the subject having an EGID status of active disease, wherein the EGID therapy is selected from proton pump inhibitor therapy, dietary therapy, anti-cytokine therapy, anti-ALOX15 therapy, anti-TSLP therapy, anti-eosinophil therapy, glucocorticoid therapy, and esophageal dilation; or
re-administering current therapy to the subject having an EGID status of managed.
|